Overview

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.

Phase:

Phase 3

Details

Lead Sponsor:

BioMarin Pharmaceutical

Treatments:

Verapamil